Noma, also known as cancrum oris, is a rapidly progressing life-threatening infection that affects the mouth and face. Noma is preventable and easy to treat if addressed in the early reversible stages, but most often deadly if untreated. The disease most commonly affects children who are chronically malnourished or whose immune systems are otherwise compromised. Noma affects an estimated 140,000 children annually. Noma was added to the WHO's list of Neglected Tropical Diseases in 2023.

MSF is working to discover more about noma. This collection highlights MSF's mixed methods research on treatment outcomes, burden of disease, attitudes towards the disease and other aspects of noma.

Antimicrobial resistance is a growing public health crisis, especially in countries with fragile health systems, population displacement or ongoing conflict. In 2019 antibiotic-resistant bacteria directly caused an estimated 1.27 million deaths, and contributed to 4.95 million deaths, tolls that will continue to increase if no effective action is taken.

MSF’s approach to combatting antimicrobial resistance combines three pillars: infection prevention and control, microbiology and surveillance, and rational use of antibiotics via antibiotic stewardship. Several studies characterize patterns and prevalence of antibiotic resistance among MSF patients, from civilians wounded in Middle East conflicts to hospitalized neonates in Central African Republic and Haiti. New technologies developed by MSF and partners are expanding local capacity for rapid, accurate laboratory diagnosis of infections, so that clinicians can prescribe the right antibiotic for each patient. Other work assesses the practices and challenges related to optimizing rational antibiotic use within health facilities and communities.